A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...
Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks ...
The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...
-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...
Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to ...
Also, a sweeping Cochrane review is fueling fresh debate over amyloid-targeting Alzheimer’s drugs. And more. The Food and ...
Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...
Investor's Business Daily on MSN
Four biotech stocks near buy points as earnings season kicks in
Four biotech stocks in the IBD 50 are in bases as first-quarter earnings rolls in. Travere Therepeutics is below a buy point ...
Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...
Yesterday, we got highly promising results from a trial of Revolution Medicines’ pancreatic cancer pill, showing that ...
Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...
In this article, we will look at the 8 Most Undervalued Biotech Stocks to Buy Right Now. On April 13, Tom Lee, Fundstrat’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results